Li, Ting-ChuanTing-ChuanLiLiu, Chih-ChunChih-ChunLiuLee, Yan-ZhangYan-ZhangLeeHsu, Yu-HoneYu-HoneHsuChiang, Chi-FengChi-FengChiangSHI-CHUEN MIAWWIN-LI LIN2020-08-142020-08-142020-04-2503603016https://scholars.lib.ntu.edu.tw/handle/123456789/512834In this study, we hypothesized that systemic antitumor immunity might be enhanced by combining pulsed-wave ultrasound hyperthermia (pUSHT) with OK-432 and that the induced antitumor immunity could confer protection against tumorigenesis. These hypotheses were tested in bilateral and rechallenged tumor models.animation[SDGs]SDG3Cell death; Diseases; Growth rate; Hyperthermia therapy; Mammals; T-cells; Ultrasonics; Anti-tumor immune; Antitumor immunity; Combination therapy; Combination treatments; Methods and materials; Pulsed-wave ultrasound; Surgical resection; Therapeutic strategy; Tumors; CD4 antigen; CD8 antigen; gamma interferon; picibanil; immunological adjuvant; picibanil; animal experiment; animal model; antineoplastic activity; Article; bilateral cancer; cancer combination chemotherapy; cancer survival; carcinogenesis; CD4+ T lymphocyte; CD8+ T lymphocyte; cell infiltration; chemoradiotherapy; controlled study; female; hyperthermia; immune response; immunocompetent cell; mouse; natural killer cell; nonhuman; priority journal; protection; pulsed ultrasound; survival rate; thermotherapy; treatment duration; tumor growth; tumor immunity; tumor volume; ultrasound therapy; animal; cell proliferation; drug effect; multimodality cancer therapy; thermotherapy; tumor cell line; ultrasound; Adjuvants, Immunologic; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Hyperthermia, Induced; Mice; Picibanil; Ultrasonic Wavesjournal article10.1016/j.ijrobp.2020.04.021323396442-s2.0-85087070677https://api.elsevier.com/content/abstract/scopus_id/85087070677https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087070677&doi=10.1016%2fj.ijrobp.2020.04.021&partnerID=40&md5=8e52ff934237c4d82f402d439183b163